(Hypertension. 2000;35:892.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From Centro de Estudos de Função Autonomica (M.J.C., M.L., J.F., A.F.d.F.), Hospital S. Joao, Oporto Medical School, Oporto, Portugal, and the Department of Internal Medicine I (A.H.v.d.M., F.B., A.J.M.i.V.), University Hospital Dijkzigt, Erasmus University, Rotterdam, the Netherlands.
Correspondence to Mario J. Carvalho, Centro de Estudos de Funçao Autonomica, Hospital de S. Joao, 4200 Oporto, Portugal. E-mail carvalho@esoterica.pt and mariocar{at}med.up.pt
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure circadian rhythm nervous system, autonomic
| Introduction |
|---|
|
|
|---|
Familial amyloid polyneuropathy (FAP) type I is a hereditary autosomal dominant disease of the peripheral nervous system with a high prevalence in the northwest of Portugal.8 Deposition of amyloid in many organs and tissues, typically the peripheral nerves, is a constant feature of FAP.8 9 The biochemical basis of the disease is a point mutation in the transthyretin (TTR) gene. The molecular variant of the TTR protein, TTR Met30, is the major component of the deposited amyloid.10 The first symptoms of FAP usually occur in the 3rd or 4th decade of life, and the disease invariably progresses to death within 8 to 15 years.8 The clinical picture is that of a mixed polyneuropathy, of both the autonomic and sensorimotor nerves.5 11
Progressive failure of the ANS eventually leading to severe incapacitating orthostatic hypotension is a clinical hallmark of FAP. This progressive failure invariably takes place within a time span of only several years. As in diabetes mellitus, involvement of the parasympathetic nervous system precedes the involvement of the sympathetic nervous system. Because of this characteristic clinical course, FAP is well suited to further clarify the role of the parasympathetic and sympathetic ANS in the regulation of the circadian BP pattern. Therefore, in a large study encompassing 245 patients with FAP at different stages of the disease, the degree of impairment of the function of the ANS was assessed and related to circadian BP patterns.
| Methods |
|---|
|
|
|---|
The patients in the study who had a sensorimotor polyneuropathy were able to stand up and walk without support, although some of them complained of postural symptoms. All patients underwent a training session to get accustomed to the different autonomic function tests.
Thirty eight apparently healthy normotensive subjects (20 males), aged 27 to 42 years, were also studied to serve as a control group.
None of the patients or control subjects used antihypertensive drugs or other agents that could interfere with ANS function. All subjects were informed about the procedures of the study and gave written informed consent. The study protocol was approved by the Institutional Ethical Committee.
Cardiovascular Autonomic Function
Thirty minutes after the insertion of a catheter (Venflon, BOC,
Ohmeda AB) in 1 of the forearm veins, cardiovascular
autonomic function was evaluated by physiological
and biochemical tests while the patients were on a motor-driven tilt
table. During the studies, ECG and finger BP (Finapres BP monitor and
Ohmeda 2300, Ohmeda) were recorded continuously, and data were
stored in a computer for offline analysis. Autonomic function
tests were always performed in the morning hours in a
temperature-controlled room.
Cardiac Parasympathetic Function
Cardiac parasympathetic function was assessed by the deep
breathing test and the Valsalva heart rate (HR) ratio. For the deep
breathing test, each patient, while in the supine position, was
instructed to breathe deeply at 6 breaths per minute. The difference
between the maximum HR during inspiration and the minimum HR during
expiration (I-E difference) was measured, and the mean of the
difference for the 6 cycles was used as an index of cardiac
parasympathetic function. An I-E difference of >15 bpm indicates
normal function, whereas an I-E difference between 5 and 15 bpm and <5
bpm indicates intermediate and severe parasympathetic dysfunction,
respectively.12 For the Valsalva maneuver, the patients
were required to maintain an expiratory pressure of 40 mm Hg for
15 seconds by blowing through a mouthpiece with the tube attached to a
mercury manometer. The Valsalva ratio was calculated by the ratio of
the highest HR during phase II to the lowest HR during phase IV
of the Valsalva maneuver. A value of
1.4 is considered to be
normal.13
Cardiovascular Sympathetic Function
Cardiovascular sympathetic function was assessed
by a 60° head-up tilt test, a Valsalva maneuver, and determination of
the plasma norepinephrine concentration.
After patients had remained in the supine position for 30 minutes, a 60° head-up tilt test was performed. This test lasted 10 minutes, unless the patients were unable to maintain the erect position because of severe orthostatic hypotension (defined as a fall in systolic BP >30 mm Hg with concomitant postural symptoms). The erect and supine systolic BPs were averaged, and their difference was calculated. Just before the head-up tilt test, blood was sampled for determination of the plasma norepinephrine concentration.
Scoring the Degree of Cardiovascular Autonomic
Involvement
To score the degree of cardiovascular autonomic
involvement in individual patients, a composite grading system was
developed (Table 1), taking the
following into account: the I-E difference to the deep breathing test,
the Valsalva ratio, the response of systolic BP to the head-up
tilt test, the BP response during phase IV of the Valsalva maneuver,
and the baseline plasma norepinephrine
concentration.14 Parasympathetic and sympathetic damage is
absent when the sum of the scores is 0 and maximal when the sum of the
scores is 9. On the basis of this grading system, 4 groups of patients,
referred to as group I (score 0, no damage of the ANS), group II (score
>0 to
3, mild damage of the ANS), group III (score >3 to
6,
moderate damage of the ANS), and group IV (score >6, severe damage of
the ANS), were distinguished (Table 2).
|
|
24-Hour Ambulatory Blood Pressure Monitoring
Twenty-fourhour ambulatory BP monitoring (No. 90207 ABP
monitor, SpaceLabs) was performed 1 day after the
cardiovascular autonomic function tests. An appropriate
cuff size, placed on the nondominant arm, was used in accordance with
the recommendations of the British Hypertension Society.15
Calibration check and instructions to the patients were made by a
trained technician according to the directions provided by SpaceLabs.
ABP was measured at 20-minute intervals during the day (9
AM to 10 PM) and at 30-minute intervals during
the night (11 PM to 8 AM). Patients were
instructed to remain in bed during the nighttime period and to be awake
and out of bed during the daytime period. The circadian BP rhythm was
evaluated by the differences of the mean systolic and
diastolic BPs during the daytime and nighttime periods.
Data Analysis
The BP and HR values from the autonomic tests were
analyzed beat by beat by use of AT- and MCA-Codas programs
(Dataq Instruments). Plasma norepinephrine concentration
was determined by fluorometric detection after separation by
high-performance liquid
chromatography.16 In 45 healthy volunteers
that were matched with FAP patients with respect to age, the mean value
of norepinephrine (range) was 202±71 (104 to 352)
pg/mL.
Data are presented as mean±SD. For comparison between the groups, a 1-way ANOVA was used. If a statistical difference was present, a Newman-Keuls multiple comparison test was used to compare differences between groups. A value of P<0.05 was considered to indicate statistical significance.
| Results |
|---|
|
|
|---|
|
Supine systolic and diastolic BP between the 4 groups did not differ, but interestingly, supine HR was higher in the patients of group II than in the other 3 groups (Table 3).
Twenty-fourhour and daytime and nighttime values of systolic and diastolic BP as well as HR between control subjects and patients of group I did not differ (Table 4). Daytime and nighttime HRs were both higher in patients of group II than in controls, but the day-night difference in HR was similar. With the progression of the impairment of the ANS, daytime and nighttime HRs as well as the day-night difference in HR progressively decreased from group II to group IV (Table 4 and Figure 1). The day-night difference in systolic and diastolic BPs was already significantly lower in patients of group II than group I because of an attenuation of the nocturnal BP decline. Because of orthostatic hypotension, daytime systolic and diastolic BPs were significantly lower in patients of groups III and IV. Because nighttime systolic and diastolic BPs between the 4 groups did not differ, the day-night difference of BP became progressively lower with progression of the impairment of the ANS (Figures 1 and 2).
|
|
|
| Discussion |
|---|
|
|
|---|
Patients of group I were still in an asymptomatic phase of their disease. It was assumed that they were close to the beginning of symptoms because they were at the age when the first symptoms of FAP usually occur. The various tests that were used were unable to detect any impairment of the ANS. This does not completely exclude the presence of some impairment of the ANS. The tests we used, although specific, might have been not sensitive enough to detect the early initial involvement of the ANS. For example, as reported previously, spectral analysis of HR in a small sample of these patients detected a decrease in the high-frequency variability of HR, compatible with involvement of the parasympathetic nervous system.17 In line with the results of the autonomic function tests, the circadian BP rhythms in patients of group I were indistinguishable from those of the control group.
Patients of group II had impairment of the parasympathetic ANS, but cardiovascular sympathetic function tests were still within the normal range. The higher HR in these patients reflects the decrease in cardiac vagal tone, leading to a predominance of the chronotropic sympathetic tone. An increase in HR has also been observed in the early phase of the autonomic neuropathy of diabetes mellitus.18 In this disorder, as in FAP, parasympathetic impairment also precedes the development of sympathetic dysfunction. Notwithstanding the impairment of parasympathetic cardiac innervation, the day-night difference of HR was maintained, suggesting that day-night variation in sympathetic tone plays an important role in the generation of the circadian variation of HR. In addition, studies in rats treated with the ganglion-blocking agent hexamethonium have provided evidence for a nonneuronal 24-hour variation of HR that is related to the degree of atrial filling and physical activity.19 Contrary to the preservation of the circadian variation of HR, the day-night difference of systolic and diastolic BP was already significantly decreased in this group of patients. This decrease in the day-night difference of BP was due to an attenuation of the nocturnal BP decline.
One may wonder how impairment of the parasympathetic ANS leads to an attenuation of this nocturnal BP decline. Because the circadian BP variation remains intact in patients undergoing cardiac pacing, it is not very likely that efferent cardiac vagal denervation, per se, is responsible for the attenuation of the nocturnal BP decline in our patients with evidence only of cardiac vagal impairment.20 On the basis of studies performed in patients with a denervated heart and in patients with an innervated heart (but with replacement of their cardiac pump function by a ventricular assist device), it has been concluded that a normally innervated heart is a prerequisite for the generation of a normal circadian BP variation.21 For this generation, afferent neural traffic from baroreceptors in the heart to the central nervous system is required. Because this traffic runs along the vagal nerve, it follows that if efferent cardiac vagal activity is impaired, afferent cardiac neural traffic is impaired as well, which we believe may well explain the attenuation of the nocturnal BP decline observed in our patients.
In groups III and IV, daytime systolic and diastolic BP decreased in parallel with the progression of sympathetic dysfunction. Because nighttime BP did not change, the progressive decline and even reversion of the day-night difference of BP were solely the result of the lower daytime BP. In contrast to observations in patient groups with other forms of autonomic failure, nocturnal or supine hypertension did not occur in our patients.22 23 24 This nocturnal hypertension is caused by centralization of the effective circulating volume during nighttime recumbence. When the function of the cardiopulmonary and arterial baroreflexes fails, as is the case in patients with autonomic failure, BP will increase. Why nocturnal hypertension did not occur in our patients, even when autonomic dysfunction was severe, is not well understood. Possibly, some degree of hypovolemia was present as a consequence of deposition of amyloid in the gastrointestinal tract and kidneys, and it interfered with the reabsorption of salt and water.
In patients of group IV and to a lesser extent in patients of group III, the diurnal BP variation mainly depended on the difference in BP between the upright and supine position that was a result of the presence of postural hypotension. Whether an intrinsic circadian pattern of BP, with lower pressures during the night and higher pressures during the day, is still present when the ANS is severely damaged remains an important question. Unfortunately, the present findings do not allow us to answer this question, because for reasons of standardization, all patients were instructed to be out of bed and not assume the supine position during the day and not to be out of bed during the night. In the future, it would be interesting to perform 24-hour ambulatory BP recordings in patients with different degrees of impairment of their ANS due to FAP while they remain supine for the whole 24-hour registration period.
In conclusion, this large study performed in subjects with impaired autonomic function due to FAP confirms the important role of the ANS in the control of the circadian BP pattern. Not only an intact sympathetic but also an intact (afferent) parasympathetic nervous system appears to be necessary for the generation of a normal circadian BP pattern. Finally, in contrast to various other autonomic disorders, severe autonomic failure in FAP is not associated with nocturnal hypertension.
Received August 24, 1999; first decision September 21, 1999; accepted November 30, 1999.
| References |
|---|
|
|
|---|
2. Tuck ML, Stern N, Sowers JR. Enhanced 24-hour norepinephrine and renin secretion in young patients with essential hypertension: relation with the circadian pattern of arterial blood pressure. Am J Cardiol. 1985;55:112115.[Medline] [Order article via Infotrieve]
3. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991;325:986990.[Abstract]
4.
Smyth HS, Sleight P, Pickering GW. Reflex regulation
of arterial pressure during sleep in man: a quantitative
method of assessing baroreflex sensitivity. Circ Res. 1969;24:109121.
5.
Mann S, Altman DG, Raftery EB, Bannister R. Circadian
variation of blood pressure in autonomic failure.
Circulation. 1983;68:477483.
6.
Omboni S, Smitt AA, Wieling W. Twenty four hour
non-invasive finger blood pressure: a novel approach to the evaluation
of treatment in patients with autonomic failure. Br Heart
J. 1995;73:290292.
7. Ikeda T, Matsubara T, Sato Y, Sakamoto N. Circadian blood pressure variation in diabetic patients with autonomic neuropathy. J Hypertens. 1993;11:581587.[Medline] [Order article via Infotrieve]
8.
Andrade C. A peculiar form of peripheral
neuropathy: familial atypical generalised amyloidosis with
special involvement of peripheral nerves. Brain. 1952;75:408427.
9.
Sobue G, Nakao N, Murakamik, Yasuda T, Sahashi K,
Mitsuma T, Sasaki H, Sasaki Y, and Takahashi A. Type I familial amyloid
polyneuropathy: a pathological study of the
peripheral nervous system. Brain. 1990;113:903919.
10. Saraiva MJ, Costa PP, Goodman DS. Biochemical marker in familial amyloidotic polyneuropathy, Portuguese type: family studies on the trans-thyretin (prealbumin)-methionine 30 variant. J Clin Invest. 1985;76:21712177.
11. Andre C, Novis SAP, Cruz MW. Familial amyloidotic polyneuropathy of the Portuguese type (type I) in Rio de Janeiro, Brazil. In: Costa PP, Falcao de Freitas, Saraiva MJ, eds. Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders. Oporto, Portugal: Arquivos de Medicina; 1990:913.
12. Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. J Clin Endocrinol Metab. 1985;15:855888.
13. Low PA. Evaluation and management. In: Low PA, ed. Clinical and Autonomic Disorders. Boston., Mass: Little Brown & Co; 1993:169195.
14.
Carvalho MJ, van den Meiracker AH, Boomsma F, Freitas
J, Man in t Veld AJ, Costa O, Falcao de Freitas A. Role of
sympathetic nervous system in cyclosporine-induced rise
in blood pressure. Hypertension. 1999;34:102106.
15. Petrie JC, OBrien ET, Littler WA, De Swiet M. Recommendations on blood pressure measurement. BMJ. 1986;93:611615.
16. van der Hoorn FAJ, Boomsma F, Man in t Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr. 1989;487:1727.[Medline] [Order article via Infotrieve]
17. Carvalho MJ, Man in t Veld AJ, Costa O, Freitas J, Puig J, Falcao de Freitas. Spectral analysis of heart rate as an assessment of autonomic function in familial amyloidotic polyneuropathy. J Hypertens. 1991;9(suppl 6):S62S63.
18. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic tests: 10 years experience in diabetes. Diabetes Care. 1985;198:491498.
19. Oosting J, Struijker-Boudier HAJ, Janssen BJA. Autonomic control of ultradian and circadian rhythms of blood pressure, heart rate, and baroreflex activity in spontaneously hypertensive rats. J Hypertens. 1997;15:401410.[Medline] [Order article via Infotrieve]
20. Davies AB, Gould BA, Cashman PM, Raftery ED. Circadian rhythm of blood pressure in patients dependent on ventricular demand pacemakers. Br Heart J. 1984;52:93698.
21.
Sehested J, Happe E, Ishino K, Hetzer R, Schiessler U,
Schifter S. Diurnal variation in blood pressure in patients with
biventricular assist devices and retained, nonpumping
native hearts. Circulation. 1994;89:26012604.
22. Mann S, Bellamy GR, Hunyor SN, Raftery EB, Ingall T, Bannister R. Supine hypertension, blood pressure variability and circadian rhythm in autonomic failure: the role of ambulatory intra-arterial monitoring. Clin Exp Pharmacol Physiol. 1984;11:347350.[Medline] [Order article via Infotrieve]
23. Plaschke M, Trenkwalder P, Dahleim H, Lechner C, Trenkwalder C. Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinsons disease and multiple system atrophy. J Hypertens. 1998;16:14331441.[Medline] [Order article via Infotrieve]
24.
Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni
I. The hypertension of autonomic failure and its treatment.
Hypertension. 1997;30:10621067.
This article has been cited by other articles:
![]() |
P. J. Davern, T.-P. Nguyen-Huu, L. La Greca, A. Abdelkader, and G. A. Head Role of the Sympathetic Nervous System in Schlager Genetically Hypertensive Mice Hypertension, October 1, 2009; 54(4): 852 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Okamoto, A. Gamboa, C. Shibao, B. K. Black, A. Diedrich, S. R. Raj, D. Robertson, and I. Biaggioni Nocturnal Blood Pressure Dipping in the Hypertension of Autonomic Failure Hypertension, February 1, 2009; 53(2): 363 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Davidson, J. K. Hix, D. G. Vidt, and D. J. Brotman Association of Impaired Diurnal Blood Pressure Variation With a Subsequent Decline in Glomerular Filtration Rate. Arch Intern Med, April 24, 2006; 166(8): 846 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Wuhl, C. Hadtstein, O. Mehls, F. Schaefer, and the ESCAPE Trial Group Ultradian but not Circadian Blood Pressure Rhythms Correlate with Renal Dysfunction in Children with Chronic Renal Failure J. Am. Soc. Nephrol., March 1, 2005; 16(3): 746 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hadtstein, E. Wuhl, M. Soergel, K. Witte, F. Schaefer, and the German Study Group for Pediatric Hypertension Normative Values for Circadian and Ultradian Cardiovascular Rhythms in Childhood Hypertension, March 1, 2004; 43(3): 547 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Poulsen Blood pressure and cardiac autonomic function in relation to risk factors and treatment perspectives in Type 1 diabetes Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 222 - 242. [Abstract] [PDF] |
||||
![]() |
K. Narkiewicz, M. Winnicki, K. Schroeder, B. G. Phillips, M. Kato, E. Cwalina, and V. K. Somers Relationship Between Muscle Sympathetic Nerve Activity and Diurnal Blood Pressure Profile Hypertension, January 1, 2002; 39(1): 168 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Baltatu, B. J. Janssen, G. Bricca, R. Plehm, J. Monti, D. Ganten, and M. Bader Alterations in Blood Pressure and Heart Rate Variability in Transgenic Rats With Low Brain Angiotensinogen Hypertension, February 1, 2001; 37(2): 408 - 413. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |